Zhejiang Medicine Co., Ltd. (600216.SS) manufactures and markets life nutrition products, pharmaceuticals, and active pharmaceutical ingredients primarily in China with global sales reach. The company produces synthetic vitamin E, natural vitamin E, vitamin A, vitamin D3, vitamin H (biotin), coenzyme Q10, beta-carotene, canthaxanthin, lutein, lycopene; pharmaceutical raw materials including anti-resistant antibiotics, antimalarial drugs, quinolones, hypoglycemic agents, hormones; finished dosage forms such as injectable levofloxacin lactate, vancomycin hydrochloride injections, teicoplanin; animal nutrition additives; human nutrition products; and aroma ingredients. Founded in 1997 through the merger of several pharmaceutical entities and headquartered in Shaoxing, Zhejiang Province, China, Zhejiang Medicine focuses on fat-soluble vitamins, carotenoids, antibiotics, and nutraceuticals for pharmaceutical, food, feed, and personal care industries, serving domestic and international markets across Asia, Europe, North America, and beyond. In a significant recent development announced in late 2025, the company plans to spin off its antibody-drug conjugate (ADC) subsidiary Novocodex for a separate listing on the Hong Kong Stock Exchange to optimize capital allocation and advance its ADC pipeline, including assets like HER2-targeting NCB001 and ARX788; Novocodex previously raised RMB 400 million in Series B funding in 2022.